Amyloid blood biomarker detects Alzheimer's disease

被引：149

作者：

Nabers, Andreas ^{[1
]}

Perna, Laura ^{[2
]}

Lange, Julia ^{[1
]}

Mons, Ute ^{[2
]}

Schartner, Jonas ^{[1
]}

Gueldenhaupt, Joern ^{[1
]}

Saum, Kai-Uwe ^{[2
]}

Janelidze, Shorena ^{[3
]}

Holleczek, Bernd ^{[4
]}

Rujescu, Dan ^{[5
]}

Hansson, Oskar ^{[3
,6
]}

Gerwert, Klaus ^{[1
]}

Brenner, Hermann ^{[2
,7
]}

机构：

[1] Ruhr Univ Bochum, Dept Biophys, Bochum, Germany

[2] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany

[3] Lund Univ, Dept Clin Sci, Lund, Sweden

[4] Saarland Canc Registry, Saarbrucken, Germany

[5] Univ Halle, Dept Psychiat Psychotherapy & Psychosomat, Halle, Germany

[6] Skane Univ Hosp, Memory Clin, Malmo, Sweden

[7] Heidelberg Univ, NAR, Heidelberg, Germany

来源：

EMBO MOLECULAR MEDICINE | 2018年 / 10卷 / 05期

基金：

欧洲研究理事会; 瑞典研究理事会;

关键词：

Alzheimer's disease diagnosis; amyloid-beta in blood plasma; BioFINDER; ESTHER; immuno-infrared-sensor; CEREBROSPINAL-FLUID; NATIONAL INSTITUTE; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; SECONDARY STRUCTURE; INFRARED-SENSOR; DEMENTIA; RECOMMENDATIONS; VALIDATION; CANDIDATE;

D O I：

10.15252/emmm.201708763

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Alzheimer's disease (AD) is currently incurable, but there is general agreement that a minimally invasive blood biomarker for screening in preclinical stages would be crucial for future therapy. Diagnostic tools for detection of AD are either invasive like cerebrospinal fluid (CSF) biomarkers or expensive such as positron emission tomography (PET) scanning. Here, we determine the secondary structure change of amyloid-beta (A beta) in human blood. This change used as blood amyloid biomarker indicates prodromal AD and correlates with CSF AD biomarkers and amyloid PET imaging in the cross-sectional BioFINDER cohort. In a further population-based longitudinal cohort (ESTHER), the blood biomarker detected AD several years before clinical diagnosis in baseline samples with a positive likelihood ratio of 7.9; that is, those who were diagnosed with AD over the years were 7.9 times more likely to test positive. This assay may open avenues for blood screening of early AD stages as a funnel for further more invasive and expensive tests.

引用

页数：11

共 38 条

[1] Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease [J].

Bateman, Randall J. ;

Xiong, Chengjie ;

Benzinger, Tammie L. S. ;

Fagan, Anne M. ;

Goate, Alison ;

Fox, Nick C. ;

Marcus, Daniel S. ;

Cairns, Nigel J. ;

Xie, Xianyun ;

Blazey, Tyler M. ;

Holtzman, David M. ;

Santacruz, Anna ;

Buckles, Virginia ;

Oliver, Angela ;

Moulder, Krista ;

Aisen, Paul S. ;

Ghetti, Bernardino ;

Klunk, William E. ;

McDade, Eric ;

Martins, Ralph N. ;

Masters, Colin L. ;

Mayeux, Richard ;

Ringman, John M. ;

Rossor, Martin N. ;

Schofield, Peter R. ;

Sperling, Reisa A. ;

Salloway, Stephen ;

Morris, John C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (09) :795-804

[2] Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010 [J].

Beach, Thomas G. ;

Monsell, Sarah E. ;

Phillips, Leslie E. ;

Kukull, Walter .

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2012, 71 (04) :266-273

[3] Amyloid biomarkers in Alzheimer's disease [J].

Blennow, Kai ;

Mattsson, Niklas ;

Scholl, Michael ;

Hansson, Oskar ;

Zetterberg, Henrik .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2015, 36 (05) :297-309

[4] Alzheimer's disease [J].

Scheltens, Philip ;

De Strooper, Bart ;

Kivipelto, Miia ;

Holstege, Henne ;

Chetelat, Gael ;

Teunissen, Charlotte E. ;

Cummings, Jeffrey ;

van der Flier, Wiesje M. .

LANCET, 2021, 397 (10284) :1577-1590

[5] Cerebrospinal fluid and plasma biomarkers in Alzheimer disease [J].

Blennow, Kaj ;

Hampel, Harald ;

Weiner, Michael ;

Zetterberg, Henrik .

NATURE REVIEWS NEUROLOGY, 2010, 6 (03) :131-144

[6] Aβ Toxicity in Alzheimer's Disease [J].

Cavallucci, Virve ;

D'Amelio, Marcello ;

Cecconi, Francesco .

MOLECULAR NEUROBIOLOGY, 2012, 45 (02) :366-378

[7] Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria [J].

Dubois, Bruno ;

Feldman, Howard H. ;

Jacova, Claudia ;

Hampel, Harald ;

Molinuevo, Jose Luis ;

Blennow, Kaj ;

Dekosky, Steven T. ;

Gauthier, Serge ;

Selkoe, Dennis ;

Bateman, Randall ;

Cappa, Stefano ;

Crutch, Sebastian ;

Engelborghs, Sebastiaan ;

Frisoni, Giovanni B. ;

Fox, Nick C. ;

Galasko, Douglas ;

Habert, Marie-Odile ;

Jicha, Gregory A. ;

Nordberg, Agneta ;

Pasquier, Florence ;

Rabinovici, Gil ;

Robert, Philippe ;

Rowe, Christopher ;

Salloway, Stephen ;

Sarazin, Marie ;

Epelbaum, Stephane ;

de Souza, Leonardo C. ;

Vellas, Bruno ;

Visser, Pieter J. ;

Schneider, Lon ;

Stern, Yaakov ;

Scheltens, Philip ;

Cummings, Jeffrey L. .

LANCET NEUROLOGY, 2014, 13 (06) :614-629

[8] Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer's Disease [J].

Fiandaca, Massimo S. ;

Zhong, Xiaogang ;

Cheema, Amrita K. ;

Orquiza, Michael H. ;

Chidambaram, Swathi ;

Tan, Ming T. ;

Gresenz, Carole Roan ;

FitzGerald, Kevin T. ;

Nalls, Mike A. ;

Singleton, Andrew B. ;

Mapstone, Mark ;

Federoff, Howard J. .

FRONTIERS IN NEUROLOGY, 2015, 6

[9] The critical need for defining preclinical biomarkers in Alzheimer's disease [J].

Fiandaca, Massimo S. ;

Mapstone, Mark E. ;

Cheema, Amrita K. ;

Federoff, Howard J. .

ALZHEIMERS & DEMENTIA, 2014, 10 (03) :S196-S212

[10] Functional waters in intraprotein proton transfer monitored by FTIR difference spectroscopy [J].

Garczarek, F ;

Gerwert, K .

NATURE, 2006, 439 (7072) :109-112

← 1 2 3 4 →